Horizon, Centauri Going to Avvinity And Beyond In New Immuno-Oncology JV
This article was originally published in Scrip
Executive Summary
The UK gene-editing group Horizon Discovery and Centauri Therapeutics Ltd hope their newly formed immuno-oncology joint venture, called Avvinity Therapeutics, will create a proprietary platform able to discover novel immuno-oncology therapies for both solid tumors and leukaemias and give them access to a market currently worth £25bn and growing rapidly.
You may also be interested in...
Finance Watch: Kallyope Leads Latest Group Of VC Mega-Rounds With $236m Raise
Private Company Edition: In other $100m-plus venture capital rounds, Third Harmonic Bio emerged with $155m, including a new $105m series B round. Also, Europe- and Japan-focused Newton Biocapital launched its second VC fund with €50m in initial capital and a €150m fundraising goal.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.